glp-1 obesity drugs The revolution: What UAB researchers are discovering about how these work GLP-1 Drugs for Weight Loss:

The foundational characterization appeared in European Journal of Endocrinology in 1998, reporting selective agonism of the growth hormone secretagogue receptor type 1a (GHS-R1a) without significant elevation of ACTH, cortisol, prolactin, FSH, LH, or TSH, even at doses 200-fold above the GH-releasing ED50 in preclinical models

Impaired Activation and Localization of LAT in Anergic T Cells as a Consequence of a Selective Palmitoylation Defect

Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors

Although both Ipamorelin and Sermorelin stimulate HGH in your body, sermorelin acts differently, in that it works to increase your body's production of HGH naturally